Francisco Partners Iv, L.P. Sells 274,717 Shares of GoodRx (NASDAQ:GDRX) Stock

GoodRx Holdings, Inc. (NASDAQ:GDRX) major shareholder Francisco Partners Iv, L.P. sold 274,717 shares of the company’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $3.50, for a total value of $961,509.50. Following the completion of the transaction, the insider directly owned 777,213 shares in the company, valued at $2,720,245.50. This represents a 26.12% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Francisco Partners Iv, L.P. also recently made the following trade(s):

• On Thursday, August 20th, Francisco Partners Iv, L.P. sold 447,259 shares of GoodRx stock. The shares were sold at an average price of $3.52, for a total value of $1,574,351.68.
• On Wednesday, August 19th, Francisco Partners Iv, L.P. sold 471,975 shares of GoodRx stock. The stock was sold at an average price of $3.53, for a total value of $1,666,071.75.

GoodRx Stock Performance

Shares of NASDAQ GDRX opened at $3.45 on Friday. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.74. The stock has a market capitalization of $1.18 billion, a price-to-earnings ratio of 86.27, a PEG ratio of 1.72 and a beta of 1.60. The stock’s fifty day simple moving average is $3.13 and its 200 day simple moving average is $2.63. GoodRx Holdings, Inc. has a 52-week low of $1.77 and a 52-week high of $5.81.

GoodRx (NASDAQ:GDRX) last announced its earnings results on Wednesday, August 5th. The company reported $0.08 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.08. GoodRx had a return on equity of 7.22% and a net margin of 2.07%.The company had revenue of $200.41 million for the quarter, compared to analyst estimates of $193.23 million. During the same period in the previous year, the firm earned $0.09 earnings per share. GoodRx’s revenue for the quarter was down 1.3% compared to the same quarter last year. As a group, sell-side analysts forecast that GoodRx Holdings, Inc. will post 0.16 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

GDRX has been the subject of a number of analyst reports. Citigroup upped their price objective on shares of GoodRx from $4.00 to $5.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. Barclays lifted their target price on shares of GoodRx from $3.00 to $4.00 and gave the stock an “underweight” rating in a research report on Thursday. UBS Group boosted their price target on shares of GoodRx from $2.50 to $3.75 and gave the company a “neutral” rating in a report on Thursday, August 13th. Leerink Partners set a $5.00 price target on shares of GoodRx in a research report on Thursday, August 6th. Finally, Wall Street Zen raised shares of GoodRx from a “hold” rating to a “buy” rating in a research note on Saturday, August 15th. Four analysts have rated the stock with a Buy rating, six have given a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $4.23.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Lazard Asset Management LLC boosted its position in GoodRx by 43.6% during the 2nd quarter. Lazard Asset Management LLC now owns 17,142 shares of the company’s stock worth $85,000 after acquiring an additional 5,201 shares during the period. Brevan Howard Capital Management LP grew its stake in GoodRx by 7.7% during the 3rd quarter. Brevan Howard Capital Management LP now owns 95,483 shares of the company’s stock valued at $404,000 after acquiring an additional 6,842 shares in the last quarter. Hirtle Callaghan & Co LLC increased its holdings in shares of GoodRx by 60.3% in the 4th quarter. Hirtle Callaghan & Co LLC now owns 18,261 shares of the company’s stock valued at $49,000 after purchasing an additional 6,869 shares during the period. Tower Research Capital LLC TRC increased its holdings in shares of GoodRx by 202.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 11,327 shares of the company’s stock valued at $56,000 after purchasing an additional 7,580 shares during the period. Finally, Quarry LP purchased a new stake in shares of GoodRx in the third quarter worth approximately $33,000. 63.77% of the stock is owned by institutional investors and hedge funds.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.